

# CHLOÉ PASIN: CV

## Postdoctoral Researcher, quantitative systems immunology & biostatistics

📍 Born 24.10.1991 in Toulouse, FR    @ chloe.pasin@usz.ch    ✉ Zurich, CH    🌐 <https://www.chloepasin.com/>  
🔗 <https://scholar.google.com/citations?user=YcIJIR0AAAAJhl=en>    🌐 <https://github.com/chlpasin>    🐦 @ChloePasin  
in <https://www.linkedin.com/in/chloe-pasin-736902a8/>

## KEY WORDS

Systems immuno-epidemiology    Population health    Human immune diversity    Infectious diseases  
Viral infections    Vaccines    Immunocompromisation    Biostatistics    AI in epidemiology    Big data science  
Effect of pathogen exposure on non-communicable diseases    Gender medicine    Health inequities

## EDUCATION AND EXPERIENCE

### University of Zurich Postdoctoral Fellow

**Institute of Medical Virology, University of Zurich / Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich**

📅 jul 2023 – present

📍 Zurich, CH

- Toward personalized vaccinology for allogeneic hematopoietic cell transplant recipients
- Socio-economic and demographic determinants of medication prescription in the Swiss HIV Cohort Study

### Collegium Helveticum Early-Career Fellow

**Collegium Helveticum, Joint Institute for Advanced Studies of the ETH Zurich, the University of Zurich, and the Zurich University of the Arts**

📅 sep 2022 – jun 2023

📍 Zurich, CH

- Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities
- The Gendered Immune System: The Missing Component in Mental Health Research

### Postdoctoral Researcher

**Institute of Medical Virology, University of Zurich / Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich**

📅 oct 2020 – aug 2022

📍 Zurich, CH

Alexandra Trkola & Roger Kouyos groups.

- Determinants of HIV-1 broadly neutralizing antibody induction
- SARS-CoV-2 seroprofiling in adults and children
- Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hemetopoietic cell transplantation

### Postdoctoral Research Scientist

**Columbia University Medical Center – Department of Pathology and Cell Biology**

📅 jan 2019 – oct 2020

📍 New York, NY, USA

Andrew Yates group.

- Predicting clinical outcomes after allogeneic hematopoietic cell transplantation based on immune reconstitution
- Vitamin D deficiency signatures after allogeneic hematopoietic cell transplantation

### PhD in Public Health, biostatistics (defense: October 30th, 2018)

**Modeling and optimizing the response to vaccine and immunotherapeutic interventions. Application to Ebola virus and HIV.**

**Université de Bordeaux / INSERM Bordeaux Population Health Research Center / INRIA Bordeaux**

📅 oct 2015 – oct 2018

📍 Bordeaux, FR

Rodolphe Thiébaud & François Dufour groups.

- Modeling the humoral immune response to Ebola vaccine. European projects EBOVAC1/2.

- Optimizing IL-7 therapies in people with HIV.
- *In silico* trials to predict the response to short-cycle strategies for HIV antiretroviral therapies
- Modeling the viral rebound kinetics following therapeutic vaccination in SIV/SHIV-infected non human primates.

---

### Predoctoral research

#### Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division

📅 oct 2014 - may 2015

📍 Seattle, WA, USA

Peter Gilbert group. Effect of rainfall season on the efficacy of a dengue vaccine in Asia and Latin America.

---

### Master of Science: Applied Mathematics - Statistic modeling in Biology.

#### Université Paris Descartes

📅 2013 - 2014

📍 Paris, FR - Bordeaux, FR

Internship: INSERM. Rodolphe Thiébaud & Daniel Commenges groups. Modeling the dynamics of CD4 T lymphocytes after HIV vaccine injection. Application to HVTN 068 clinical trial.

---

### Master's degree: Applied Mathematics

#### ENS Cachan / Université Paris Diderot

📅 2012 - 2013

📍 Paris, FR - Canberra, AUS

Internship: NICTA (now CSIRO), Canberra, Australia. Bob Williamson group.

---

### Bachelor's degree: Mathematics

#### ENS Cachan / Université Paris Diderot

📅 2011 - 2012

📍 Cachan, FR

Internship: CMLA, Cachan. Nicolas Vayatis group.

---

### Entry at Ecole Normale Supérieure de Cachan - now Ecole Normale Supérieure Paris Saclay (2011)

## FUNDINGS

---

- University of Zurich postdoc fellowship (approx. CHF 115,000): Toward personalized vaccinology for allogeneic hematopoietic cell transplant recipients (2024).
- Swiss HIV Cohort Study funding (approx. CHF 26,000): Socio-economic and demographic determinants of medication prescription in the Swiss HIV Cohort Study (2023).
- Collegium Helveticum fellowship (approx. CHF 85,000): The Gendered Immune System: The Missing Component in Mental Health Research (Sep 2022 - Jun 2023)
- UZH GRC Short grant (approx. CHF 4,000): organization of the workshop "Sex and gender in immunity" at the Collegium Helveticum, Zurich (May 5-6, 2022)
- Swiss HIV Cohort Study funding (approx. CHF 44,000): Women and HIV: a spotlight on the role of oestrogens and progestogens on the immune system (2021).
- Philippe Foundation grant (support for research activities between France and the US, 2019-2020): \$9,000
- PhD grant (French ministry of education, 2015-2018)

## HONORS AND AWARDS

---

- Pfizer Research Prize in the field Infectious Diseases, Rheumatology, and Immunology (2023) for *Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity*
- Second prize of the Swiss Society for Infectious Diseases in the category "clinical research in infectious diseases" for *Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity*

## MENTORING AND TEACHING ACTIVITIES

---

Supervision:

- Marco Labarile, UZH (PhD student, in thesis committee).
- Nadia Neuner-Jehle, UZH (Master student). Currently PhD student in Emma Hodcroft group (University of Basel).

- Marius Zeeb, UZH (PhD student).
- Lise Gross, U. Bordeaux (Master student).

#### Teaching:

- Teaching in the Certificate of Advanced Studies in Sex- and Gender- Specific Medicine, session on Infectious Diseases, University of Zurich and University of Bern (2024).
- Teaching in the block course Quantitative Life Sciences: from Infectious Diseases to Ecosystems, University of Zurich (teaching assistant since 2020, talk on quantitative immunology since 2023).
- Total of 128h of teaching at ISPED (Institut de Santé Publique, d'Épidémiologie et de Développement) in the following courses: linear mixed models (MSC: epidemiology), linear regression & statistical tests (Master: Public Health), statistical modeling (Public Health residents). Softwares R and SAS.

## INSTITUTIONAL RESPONSIBILITIES

---

- Initiator and part of the University of Zurich free menstrual products working group. Pilot project launched in fall 2023.
- Elected at the Equal Opportunities Commission of University of Zurich (sep 2021 - jun 2022).
- Active member in the Columbia postdoctoral workers union (sep 2019 - sep 2020).
- PhD students' representative at the INSERM U1219 center committee (2018).
- PhD students' representative at the doctoral college of the University of Bordeaux (2017-2018).
- PhD students' representative at the doctoral school committee (2015-2016).
- Treasurer of the PhD student's association of the doctoral school (2015-2016).

## MEMBERSHIPS AND SCIENTIFIC REVIEWING

---

- Member of the Swiss HIV Cohort Study Young Researchers' Group (since 2022)
- Member of WAVE group (Women Against Viruses in Europe) and EACS (European AIDS Clinical Society) (since 2021)
- Member of AAI (American Association of Immunologists), attendance to AAI Advanced Course in Immunology (2019)
- Member of 500 Women Scientists (since 2019)
- Member of SFdS (French Society of Statistics) and SMAI (Société de Mathématiques Appliquées et Industrielles) (2016-2018)
- Reviews: 3Rs French center fundings (2024), Plos Computational Biology (since 2020), Plos Pathogens (2021), and Nature Computational Science (2021)

## WORKSHOP ORGANISATION

---

- "Integrating diverse forms of knowledge in health care research" at the Collegium Helveticum, Zurich, June 2023
- "Sex and gender in immunity" at the Collegium Helveticum, Zurich, May 2022
- "Communicating effectively online" with the Columbia University Postdoctoral Society (may 2020)

## OUTREACH ACTIVITIES

---

- Scientific input for an article in El País by a scientific journalist (¿Por qué hablamos del 70% de población vacunada como 'cifra mágica' para acabar con la covid?, April 14th 2021)
- Training in science communication: SCOPE (Science Communication Online Programme from Northwestern University). Online class with 8 modules, designed by science-communication experts (2020).
- Data for the People (D4P), *Episode #6: Math, Models, and Social Mixing*. Presentation of a paper on modeling COVID-19 epidemic. Organised by RockEDU (Rockefeller University, NY). Replay available on Youtube. (2020)
- Member of the communication & outreach committee of CUPS - Columbia University Postdoctoral Society (2019 - 2020). Organisation of a workshop "Communicating effectively online" (may 2020) and trivia nights.
- Participation in outreach events (2019) : Girls' Science Day (Columbia University, Spring and Fall), STEM expo (Harlem).
- Association "Women and Science". Interventions in mid and high schools (Bordeaux, 2017).

## PUBLICATIONS

---

*In chronological order. Shared first and last authorship are represented with \* and §, respectively.*

**Postdoctoral period:**

1. Abela IA, Chammartin F, Amstutz A, Surial B, Ballif M, Marzolini C, Aebi-Popp K, Notter J, Segeral O, Stoeckle M, Cavassini M, Bernasconi E, Günthard HF, Kouyos RD, [Pasin C](#), and the Swiss HIV Cohort Study. **Gender disparities in statins prescriptions in people with HIV with low/moderate to high cardiovascular risk.** Under revision at Open Forum Infectious Diseases.
2. Jackson-Perry D, Cart-Richter E, Haerry D, Ahmeti L, Bieri A, Calmy A, Ballif M, [Pasin C](#), Notter J, Amstutz A. **Patient and Public Involvement in HIV research: a mapping review and development of an online evidence map.** Under revision at Journal of the International AIDS Society.
3. Neuner-Jehle N, Zeeb M, Thorball CW, Fellay J, Metzner KJ, Frischknecht P, Neumann K, Leeman C, Rauch A, Stöckle M, Huber M, Perreau M, Bernasconi E, Notter J, Hoffmann M, Leuzinger K, Günthard HF, [Pasin C](#)<sup>§</sup>, Kouyos RD<sup>§</sup> and the Swiss HIV Cohort Study. **Using Viral Diversity to Identify HIV-1 Variants Under HLA-Dependent Selection in a Systematic Viral Genome-Wide Screen.** Plos Pathogens. 2024.
4. [Pasin C](#), Garnia Nunez D, Kusejko K, Hachfeld A, Buvelot H, Cavassini M, Damonti L, Fux C, Martinez de Tejada B, Notter J, Trkola A, Günthard HF, Aebi-Popp K<sup>§</sup>, Kouyos RD<sup>§</sup>, Abela IA<sup>§</sup>, and the Swiss HIV Cohort Study. **Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.** HIV medicine. 2024.
5. Zeeb M, [Pasin C](#), Cavassini M, Bieler-Aeschlimann M, Frischknecht P, Kusejko K, Fellay J, Blanquart F, Metzner KJ, Neumann K, Jörimann L, Tschumi J, Bernasconi E, Huber M, Kovari H, Leuzinger K, Notter J, Perreau M, Rauch A, Ramette A, Stöckle M, Yerly S, Günthard HF<sup>§</sup>, Kouyos RD<sup>§</sup>, and the Swiss HIV Cohort Study. **Self-reported neurocognitive complaints in the Swiss HIV Cohort Study – a viral genome wide association study.** Brain Communications. 2024.
6. Trepl J\*, [Pasin C](#)\*, Schneidawind D, Mueller NJ, Manz MG, Bankova AK<sup>§</sup>, Abela IA<sup>§</sup>. **Evaluating Tixagevimab/Cilgavimab Prophylaxis in Allogeneic Hematopoietic Cell Transplantation Recipients for COVID-19 Prevention.** British Journal of Haematology, 2024.
7. Abela IA, Schwarzmüller M, Ulyte A, Radtke T, Haile SR, Ammann P, Raineri A, Ruegg S, Epp S, Berger C, Böni J, Manrique A, Audige A, Huber M, Scheriber PW, Scheier T, Fehr J, Weber J, Rusert P, Günthard HF, Kouyos RD, Puhan MA, Kriemler S, Trkola A, [Pasin C](#). **Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.** mBio, 2024.
8. Abela IA\*, Hauser A\*, Schwarzmüller M\*, [Pasin C](#)\*, Kusejko K, Epp S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux CA, Leuzinger K, Perreau M, Ramette A, Gottschalk J, Schindler E, Wepf A, Marconato M, Manz MG, Frey BM, Braun DL, Huber M, Günthard HF<sup>§</sup>, Trkola A<sup>§</sup>, Kouyos RD<sup>§</sup>, and the Swiss HIV Cohort Study. **Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study.** The Journal of Infectious Diseases, 2024.
9. Turk T\*, Labarile M\*, Braun DL, Rauch A, Stoeckle M, Cavassini M, Hoffmann M, Calmy A, Bernasconi E, Notter J, [Pasin C](#)<sup>§</sup>, Günthard HF<sup>§</sup>, Kouyos RD<sup>§</sup>, and the Swiss HIV Cohort Study. **Characterization and determinants of long-term immune recovery under suppressive antiretroviral therapy.** JAIDS, 2024.
10. Maliqi L\*, Friedrich N\*, Glögl M, Schmutz S, Schmidt D, Rusert P, Schanz M, Zaheri M, [Pasin C](#), Niklaus C, Foulkes C, Reinberg T, Dreier B, Abela IA, Peterhoff D, Hauser A, Kouyos RD, Günthard HF, van Gils MJ, Sanders RW, Wagner R, Plückthun A, Trkola A. **Assessing immunogenicity barriers of the HIV-1 envelope trimer.** npj Vaccines, 2023.
11. [Pasin C](#), Consiglio CR, Huisman JS, de Lange AMG, Peckham H, Vallejo-Yagüe E, Abela IA, Islander U, Neuner-Jehle N, Pujantell M, Roth O, Schirmer M, Tepekule B, Zeeb M, Hachfeld A, Aebi-Popp K, Kouyos RD<sup>§</sup>, Bonhoeffer S<sup>§</sup>. **Sex and gender in infection and immunity: Addressing the bottlenecks from basic science to public health and clinical applications.** Royal Society Open Science, 2023.
12. Clairon Q, [Pasin C](#), Balelli I, Thiébaud R, Prague M. **Parameter estimation in nonlinear mixed effect models based on ordinary differential equations: an optimal control approach.** Computational Statistics, 2023.
13. Brown JA\*, Hauser A\*, Abela IA\*, [Pasin C](#), Epp S, Mohloanyana T, Nsakala BL, Trkola A, Labhardt N<sup>§</sup>, Kouyos RD<sup>§</sup>, Günthard HF<sup>§</sup>. **Seroprevalence of antibodies against endemic human coronaviruses and SARS-CoV-2 in an HIV cohort in Lesotho: correlates of antibody response and seropositivity.** The Journal of Infectious Diseases, 2023.
14. Labarile M, Loosli T, Zeeb M, Kusejko K, Huber M, Hirsch HH, Perreau M, Ramette A, Yerly S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux C, Günthard HF<sup>§</sup>, [Pasin C](#)<sup>§</sup>, Kouyos RD<sup>§</sup>, and the Swiss HIV Cohort Study. **Quantifying and predicting ongoing HIV transmission dynamics in the Swiss HIV Cohort Study using a distance-based clustering approach.** The Journal of Infectious Diseases, 2022.
15. Bankova AK\*, [Pasin C](#)\*, Huang A, Cicin-Sain C, Epp S, Audige A, Mueller NJ, Nilsson K, Vilinovszki O, Nair G, Wolfgensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel AS, Manz MG, Abela IA<sup>§</sup>, Müller AMS<sup>§</sup>. **Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic hematopoietic cell transplantation.** British Journal of Haematology, 2022.
16. Chammartin F, Kusejko K, [Pasin C](#), Trkola A, Briel M, Amico P, Stoeckle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Müller T, Tamm M, Mueller NJ, Rauch A, Koller MT, Günthard HF, Bucher HC, Speich B, Abela IA, and the Swiss HIV Cohort Study. **Determinants of antibody response to SARS-CoV-2 mRNA vaccines in people living with HIV.** AIDS, 2022.

17. Marconato M\*, Abela IA\*, Hauser A\*, Schwarzmueller M, Katzensteiner R, Braun DL, Epp S, Audigé A, Weber J, Rusert P, Schindler E, Pasin C, West E, Boeni J, Kufner V, Huber M, Zaheri M, Schmutz S, Frey BM, Kouyos RD<sup>§</sup>, Günthard HF<sup>§</sup>, Manz MG<sup>§</sup>, Trkola A<sup>§</sup>. **Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy.** *Journal of Clinical Investigation*, 2022.
18. Huang A\*, Cicin-Sain C\*, Pasin C\*, Epp S, Audigé A, Müller NJ, Nilsson J, Bankova A, Wolfensberger N, Vilirovski O, Nair G, Hockl P, Schanz U, Kouyos RD, Hasse B, Zinkernagel AS, Trkola A, Manz MG, Abela IA<sup>§</sup>, Müller AMS<sup>§</sup>. **Antibody Response to SARS-CoV-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and Cellular Therapy*, 2021.
19. Abela IA\*, Pasin C\*, Schwarzmueller M\*, Epp S, Sickmann ME, Schanz ME, Rusert P, Weber J, Schmutz S, Audigé A, Maliqi L, Hunziker A, Hesselman MC, Niklaus CR, Gottschalk J, Schindler E, Wepf A, Karrer U, Wolfensberger A, Rampini SK, Meyer Sauter PM, Berger C, Huber M, Böni J, Braun DL, Marconato M, Manz MG, Frey BM, Günthard HF<sup>§</sup>, Kouyos RD<sup>§</sup>, Trkola A<sup>§</sup>. **Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.** *Nature Communications*, 2021.
20. Macedo R\*, Pasin C\*, Ganetsky A\*, Harle D, Wang XK, Belay K, Richman LP, Huffman AP, Vonderheide RH, Yates AJ, Porter DL, Wang Y, Zhang Y, Reshef R. **Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EHZ2-ID3 signature.** *Transplantation and Cellular Therapy*, 2021.
21. Szabo PA, Dogra P, Gray JI, Wells SB, Connors TJ, Weisberg SP, Krupska I, Matsumoto R, Poon MML, Idzikowski E, Morris SE, Pasin C, Yates AJ, Ku A, Chait M, Davis-Porada J, Zhou J, Steinle M, Mackay S, Saqi A, Baldwin MR, Sims PA, Farber DL. **Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19.** *Immunity*, 2021.
22. Pasin C, Moy RH, Reshef R, Yates AJ. **Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation.** *Scientific Reports*, 2021.
23. Balelli I, Pasin C, Prague M, Crauste F, Van Effelterre T, Bockstal V, Solforosi L, Thiébaud R. **A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus.** *Journal of Theoretical Biology*, 2020.

#### PhD and prior:

24. Pasin C, Balelli I, Van Effelterre T, Bockstal V, Solforosi L, Prague M, Douoguih M, Thiébaud R, for the EBOVAC1 consortium. **Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation.** *Journal of Virology*, 2019.
25. Villain L, Commenges D, Pasin C, Prague M, Thiébaud R. **Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts.** *Statistics in medicine*, 2019.
26. Pasin C, Dufour F, Villain L, Zhang H, Thiébaud R. **Controlling IL-7 injections in HIV-infected patients.** *Bulletin of Mathematical Biology*, 2018.
27. Gross L, Lhomme E, Pasin C, Richert L, Thiébaud R. **Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination.** *International Journal of Infectious Diseases*, 2018.
28. Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P, Capeding MR, Carrasquilla G, Frago C, Cortés M, Chambonneau L, Moodie Z. **Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.** *Plos One*, 2018.
29. Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa SC, Thiébaud R. **Early CD4+ T cell responses are associated with subsequent CD8+ T cell responses to an rAd5-based prophylactic prime-boost HIV vaccine strategy.** *PLOS ONE*, 2016.

#### Contributions to books

30. Thiébaud R, Villain L, Pasin C, Commenges D. **Modelling the response to Interleukin-7 Therapy in HIV-infected patients.**, chapter in Molina-Paris C & Lythe G. *Mathematical, Computational and Experimental T Cell Immunology*, Springer, 2020.

#### Peer-reviewed conference proceedings

31. Cicin-Sain C, Huang A, Pasin C, Epp S, Mueller NJ, Nilsson J, Vilirovski O, Nair G, Wolfensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel A, Manz MG, Abela IA, Mueller AMS. **Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation.** In *Blood* (2021) 138 (Supplement 1): 3894.
32. Pasin C, Reshef R, Yates AJ. **Use of variable selection methods to identify clinical and immunologic factors associated with the clinical outcome of patients following allogeneic hematopoietic stem cell transplantation.** In *Bone Marrow Transplantation* 2020 Dec 1 (Vol 55, No suppl 1, pp. 793-794).
33. Steinwart I, Pasin C, Williamson R, Zhang S. **Elicitation and identification of properties.** In *Conference on Learning*

## Preprints

34. Prague M, Jeffrey MG, Balelli I, Pasin C, Li JZ, Barouch DH, Whitney JB, Hill AL. **Viral rebound kinetics following single and combination immunotherapy for HIV/SIV.** BioRxiv, 2019.

## ORAL CONTRIBUTIONS TO CONFERENCES

---

### Talks in peer-reviewed international conferences:

1. Pasin C, Villain L, Dufour F, Commenges D, Prague M, Thiébaud R. **Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients.** PAGE (Population Approach Group Europe) meeting, Montreux, Switzerland, 2018.
2. Pasin C, Prague M, Eggo R, Van Effelterre T, Balelli I, Snape M, Anzala O, Praygod G, Anywaine Z, Solforosi L, Verbruggen N, Bockstal V, Watson-Jones D, Edmunds J, Douoguih M, Thiébaud R. **Modelling the humoral immune response to Ebola vaccine. Results from EBOVAC1 project.** Systems Immunology & Vaccine Design symposium, Heidelberg, Germany, 2017.
3. Pasin C, Richert L, Commenges D, Thiébaud R. **Modelling the immune response to HIV vaccine.** British Society for Immunology meeting, Cambridge, UK, 2015.

### Talks in peer-reviewed french conferences:

4. Pasin C, Dufour F, Thiébaud R. **Optimisation des stratégies d'injection d'interleukine 7 pour des patients infectés par le VIH.** SMAI 2017, 8ème biennale des Mathématiques Appliquées et Industrielles, Ronce-les Bains, 2017.
5. Pasin C, Richert L, Commenges D, Thiébaud R. **Modélisation de la réponse à un vaccin VIH.** GDR Statistiques et Santé, Paris, 2015.

### Talks in invited conferences and seminars:

6. Pasin C, Thiébaud R. **Modelling the humoral immune response to Ebola vaccine.** Joint EBOVAC1 & EBOVAC2 1st, 2nd and 3rd annual meetings (Paris 2016, Windsor 2016, Amsterdam 2018).
7. Pasin C, Dufour F, Thiébaud R. **Optimal administration of IL-7 in HIV-infected patients.** Séminaires de Probabilités et Statistiques, Montpellier, France, 2017.
8. Pasin C, Thiébaud R. **Modelling the humoral immune response to Ebola vaccine.** Bordeaux Modelling Workshop, Bordeaux, France, 2016.
9. Pasin C, Dufour F, Thiébaud R. **Optimal administration of IL-7 in HIV-infected patients.** Bordeaux Modelling Workshop, Bordeaux, France, 2016.
10. Pasin C, Commenges D, Jarne A, Richert L, Lhomme E, Thiébaud R. **Mechanistic modelling of CD4+ T cell response to rAd5/DNA HIV vaccine.** Bordeaux Modelling Workshop, Bordeaux, France, 2014.

### Posters in peer-reviewed international conferences:

11. Pasin C, Amstutz A, Chammartin F, Surial B, Ballif M, Marzolini C, Aebi-Popp K, Notter J, Segeral O, Stoeckle M, Cavassini M, Bernasconi E, Günthard HF, Abela IA, Kouyos RD, and the Swiss HIV Cohort Study. **Socio-economic and demographic determinants of medication prescription in the Swiss HIV Cohort Study.** EACS (European AIDS Conference) 2023.
12. Pasin C\*, Rusert P\*, Friedrich N, Schanz M, Glögl M, Rauch A, Cavassini M, Calmy A, Stöckle M, Kouyos RD, Günthard HF, Trkola A, and the Swiss HIV Cohort Study. **Virus panel classification: a strategy towards delineation of plasma bnAb activity.** CROI (Conference on Retroviruses and Opportunistic Infections) 2023.
13. Abela I\*, Pasin C\*, Friedrich N\*, Rusert P, Schanz M, Wagner R, Sanders R, van Gils M, Weissenhorn W, Kwong PD, Günthard HF, Kouyos RD, Trkola A, and the Swiss HIV Cohort Study. **Inferring immunogenic properties of Env trimers by reactivity to bnAb inducer plasma.** CROI (Conference on Retroviruses and Opportunistic Infections) 2023.
14. Pasin C, Garcia Nuñez D, Kusejko K, Aebi-Popp K, Hachfeld A, Buvelot H, Cavassini M, Damonti L, Fux C, Martinez de Tejada B, Notter J, Trkola A, Günthard H, Kouyos R<sup>§</sup>, Abela I<sup>§</sup>, and the Swiss HIV Cohort Study. **Distinct effect of sex hormone intake on immunity in cis and trans women with HIV.** CROI (Conference on Retroviruses and Opportunistic Infections) 2023.
15. Abela I\*, Hauser A\*, Pasin C\*, Schwarzmüller M\*, Günthard HF, Trkola A, Kouyos R. **Respiratory disease factors link with reduced SARS-CoV-2 susceptibility in PWH.** CROI (Conference on Retroviruses and Opportunistic Infections) 2023.
16. Abela I\*, Pasin C\*, Schwarzmüller M, Ulyte A, Radtke T, Audigé A, Huber M, Berger C, Hasse B, Rusert P, Günthard HF, Kouyos R, Puhon M, Kriemler S, Trkola A. **Delineating factors associated with asymptomatic primary SARS-CoV-2 infection.** CROI (Conference on Retroviruses and Opportunistic Infections) 2023.
17. Pasin C, Reshef R, Yates AJ. **Use of variable selection methods to identify clinical and immunologic factors associated with the clinical outcome of patients following allogeneic hematopoietic stem cell transplantation.** 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, online, 2020.
18. Pasin C, Villain L, Dufour F, Thiébaud R. **Optimal administration of IL-7 in HIV-infected patients.** Systems Approaches in Immunology and Infectious Diseases, Santa Fe, NM, USA. 2016.